- $1.16m
- -$2.93m
- 12
- 51
- 13
- 15
Annual cashflow statement for GRI Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -3.46 | -4.82 | -9.3 | -7.02 | -13 |
| Depreciation | |||||
| Non-Cash Items | 0.405 | 0.154 | 0.686 | 0.249 | 2.36 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.16 | 0.887 | 0.22 | -0.566 | 1.68 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -2.88 | -3.71 | -8.31 | -7.13 | -8.99 |
| Capital Expenditures | 0 | -0.002 | 0 | — | -0.008 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -3.84 | 3.78 | — |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0 | -0.002 | -3.84 | 3.78 | -0.008 |
| Financing Cash Flow Items | -0.01 | 0 | — | — | 0.269 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 6.09 | -0.004 | 15.7 | 3.43 | 10.8 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.21 | -3.71 | 3.59 | 0.079 | 1.8 |